Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes

Medicine and Dentistry

• Adverse Event 20%
• Aflibercept 100%
• Assessment 20%
• Atrophy 40%
• Best Corrected Visual Acuity 40%
• Bevacizumab 20%
• Bleeding 20%
• Fluorescein Angiography 20%
• Injection 40%
• Loading Drug Dose 20%
• Optical Coherence Tomography 40%
• Patient 60%
• Randomized Clinical Trial 20%
• Ranibizumab 20%
• Retinal Pigment Epithelium 40%
• Subretinal Fluid 20%
• Therapeutic Procedure 100%
• Thromboembolism 20%
• Vision 20%
• Wet Macular Degeneration 100%

Nursing and Health Professions

• Adverse Event 20%
• Aflibercept 100%
• Atrophy 40%
• Best Corrected Visual Acuity 40%
• Bevacizumab 20%
• Bleeding 20%
• Central Retinal Thickness 40%
• Fluorescence Angiography 20%
• Injection 40%
• Loading Drug Dose 20%
• Optical Coherence Tomography 40%
• Ranibizumab 20%
• Subretinal Fluid 20%
• Thromboembolism 20%
• Visual Pigment 40%
• Wet Macular Degeneration 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Aflibercept 100%
• Atrophy 40%
• Bevacizumab 20%
• Bleeding 20%
• Fluorescein 20%
• Ranibizumab 20%
• Subretinal Fluid 20%
• Thromboembolism 20%
• Visual Pigment 40%
• Wet Macular Degeneration 100%